Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Super-Affinity Antibody

InVivoMAb Anti-Mouse NKG2D & CD3e Bispecific Antibody (Iv0248)

Catalog #:   VMD72101 Specific References (50) DATASHEET
Host species: Mouse
Isotype: IgG
Applications: FuncS
Accession: O54709 & P22646
Overview

Catalog No.

VMD72101

Species reactivity

Mouse

Host species

Mouse

Isotype

IgG

Clonality

Monoclonal

Target

Bispecific, NKG2-D type II integral membrane protein, Killer cell lectin-like receptor subfamily K member 1, NK cell receptor D, NKG2-D-activating NK receptor, CD314, Klrk1, Nkg2d, T-cell surface glycoprotein CD3 epsilon chain, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, Cd3e

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

O54709 & P22646

Applications

FuncS

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

Iv0248

Data Image
References

Synthetic NKG2D receptor (SNR) armored CAR-T cells overcome antigen heterogeneity of solid tumor., PMID:40536708

T cell-mediated immune surveillance conferred by latent Epstein-Barr virus genes suppresses a broad spectrum of tumor formation through NKG2D-NKG2DL interactions., PMID:40534857

Photoactivatable Exosenolytics Activate Natural Killer Cells for Delaying Osteoarthritis., PMID:40534503

A fc-engineered NKG2D × B7-H3 bispecific antibody enhances the antitumor activity by orchestrating cytotoxic lymphocytes., PMID:40516256

Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update., PMID:40513285

Harnessing NKG2D CAR-T cells with radiotherapy: a novel approach for esophageal squamous cell carcinoma treatment., PMID:40510363

Regulatory TCRαβ+ double negative T cells suppress γδ T cells and alleviate colitis., PMID:40505772

Exploring the correlation and mechanism of natural killer cell cytotoxic sensitivity against gastric cancer., PMID:40486876

Dysregulation of NK cell subsets and phenotypes in COVID-19 patients with comorbid type 2 diabetes., PMID:40471558

Myeloid cell IL-15 production in the brain supports Bystander CD8+ T-Cell Neuropathic Immune Responses following Virus infection., PMID:40462933

Two major human phenotypes of MICA molecules and their differential activation to NK cells via NKG2D receptor., PMID:40458406

Curcumin combined with arsenic trioxide enhances autophagy and immune surveillance to inhibit immune escape in acute myeloid leukemia., PMID:40440957

Intraperitoneal infusion of NKG2D CAR-NK cells induces endogenous CD8+ T cell activation in patients with advanced colorectal cancer., PMID:40437757

Natural Killer Cell Activation Signature Identifies Cyclin B1/CDK1 as a Druggable Target to Overcome Natural Killer Cell Dysfunction and Tumor Invasiveness in Melanoma., PMID:40430484

Inhibition of MCP1 (CCL2) Enhances Antitumor Activity of NK Cells Against HCC Cells Under Hypoxia., PMID:40430040

Intratumoral Injection of Allogeneic NK Cell With Chemotherapy in a Triple-negative Breast Cancer Preclinical Model., PMID:40425335

Distinct immunity dynamics of natural killer cells in mild and moderate COVID-19 cases during the Omicron variant phase., PMID:40421029

NKG2D triggering hampers DNAM-1-mediated signaling in human NK cells., PMID:40421025

Tandem CAR T-cells targeting CD19 and NKG2DL can overcome CD19 antigen escape in B-ALL., PMID:40416955

Complete CD16A Deficiency and Defective NK Cell Function in a Man Living with HIV., PMID:40411624

IL-15-Activated CD38+HLA-DR+CD8+ T cells induce liver injury in cirrhosis via JAK/STAT5 and PI3K/mTOR pathways., PMID:40399368

Itolizumab regulates activating and inhibitory signals on effector cells, improving their cytotoxicity against CD318+ tumor cell lines., PMID:40391211

N6-methyladenosine RNA base modification regulates NKG2D-dependent and cytotoxic genes expression in natural killer cells., PMID:40389988

Rationale and feasibility of a rapid integral biomarker program that informs immune-oncology clinical trials: the ADVISE trial., PMID:40389374

Whole-Blood RNA Sequencing Profiling of Patients With Rheumatoid Arthritis Treated With Tofacitinib., PMID:40388487

Macrophage-derived pro-inflammatory cytokines augment the cytotoxicity of cytokine-induced killer cells by strengthening the NKG2D pathway in multiple myeloma., PMID:40369131

Protocol for in-plate staining of clinical peripheral blood mononuclear cell samples for high-throughput analysis via spectral flow cytometry., PMID:40347474

Higher CD16-NKp46bright uterine endometrial natural killer cells may predict pregnancy success in women experiencing recurrent reproductive failure., PMID:40318990

A multidimensional analysis of prognostic factors in atopic dermatitis., PMID:40313541

Epigenetic silencing of DNA sensing pathway by FOXM1 blocks stress ligand-dependent antitumor immunity and immune memory., PMID:40295473

Identifying Modifiers of CAR T-Cell Therapeutic Efficacy and Safety: A Systematic Review and Individual Patient Data Meta-Analysis., PMID:40280037

NKG2D-CAR-targeted iPSC-derived MSCs efficiently target solid tumors expressing NKG2D ligand., PMID:40276759

CLN-619, a MICA/B monoclonal antibody that promotes innate immune cell-mediated antitumor activity., PMID:40274283

Cytokine Expression and Cytolytic Effect of Natural Killer Cells are Suppressed in Septic Shock., PMID:40254928

ULBP2 Promotes Tumor Progression by Suppressing NKG2D-Mediated Anti-Tumor Immunity., PMID:40243581

Dual modulation of cytotoxic and checkpoint receptors tunes the efficacy of adoptive Delta One T cell therapy against colorectal cancer., PMID:40240620

Heterogeneity of γδ T-cell subsets and their clinical correlation in patients with AML., PMID:40236710

From genetic variants to therapeutic targets: insights into understanding rheumatoid arthritis., PMID:40236704

CD155 blockade enhances allogeneic natural killer cell-mediated antitumor response against osteosarcoma., PMID:40234092

Ribosomal protein L9 is a potential therapeutic target for B-ALL through the activation of the p53 signaling pathway., PMID:40213545

H3K27M diffuse midline glioma is homologous recombination defective and sensitized to radiotherapy and NK cell-mediated antitumor immunity by PARP inhibition., PMID:40207661

NKG2D ligand expression on NK cells induces NKG2D-mediated cross-tolerization of cytokine signaling and reduces NK cell tumor immunity., PMID:40199610

Spatial statistics of submicron size clusters of activating and inhibitory Natural Killer cell receptors in the resting state regulate early time signal discrimination., PMID:40196617

NKG2D/CD28 chimeric receptor boosts cytotoxicity and durability of CAR-T cells for solid and hematological tumors., PMID:40181405

Immune signatures and biomarkers of viral control in early-treated children with HIV: insights informing intervention., PMID:40171852

Effects of two different variants in the MAGT1 gene on B cell subsets, platelet function, and cell glycome composition., PMID:40170846

Immune profile and routine laboratory indicator-based machine learning for prediction of lung cancer., PMID:40168805

Enrichment of CD7+CXCR3+ CAR T-cells in infusion products is associated with durable remission in relapsed or refractory diffuse large B-cell lymphoma., PMID:40132760

23ME-01473, an Fc Effector-Enhanced Anti-ULBP6/2/5 Antibody, Restores NK Cell-Mediated Antitumor Immunity through NKG2D and FcγRIIIa Activation., PMID:40116579

CD4+ anti-TGF-β CAR T cells and CD8+ conventional CAR T cells exhibit synergistic antitumor effects., PMID:40107245

Datasheet
$ 484
Product specifications
100 μg 484 1 mg 1932

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

InVivoMAb Anti-Mouse NKG2D & CD3e Bispecific Antibody (Iv0248) [VMD72101]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only